Novo Nordisk launches Wegovy oral pill, unveils pricing
Novo Nordisk launched an FDA‑approved oral Wegovy semaglutide pill in the US, offering needle‑free dosing; multiple strengths priced up to $299 monthly, raising affordability concerns.
SemaforNovo Nordisk launches weight loss pill in US
Scientific AmericanWegovy Weight-Loss Pills Are Now Available in the U.S.—Here’s What That Means
Daily BeastWegovyâs Weight-Loss Pill Is Now AvailableâHereâs How Much It Costs
:max_bytes(150000):strip_icc():focal(749x0:751x2)/wegovy-pill-010526-2be253e997d144e2866dfb10b57a5663.jpg)
PeopleThe Wegovy Pill Is Now Available. Here's How to Get It — and How Much It Costs
Overview
Novo Nordisk launched a pill version of its Wegovy weight‑loss drug in the United States after FDA approval, marking the first oral GLP‑1 obesity medication available nationally.
The 4 mg pill is $149 monthly through April 15, rising to $199 thereafter; higher 9 mg and 25 mg doses cost $299, matching cash prices for injections.
Wegovy oral contains semaglutide, the same active ingredient as injectable Wegovy and Ozempic; it must be taken on an empty stomach with water, wait 30 minutes before eating.
Clinical trials showed up to 16.6% weight loss with Novo Nordisk's oral semaglutide; Eli Lilly's orforglipron achieved about 11%, intensifying market competition.
Common GLP‑1 side effects include nausea, vomiting, diarrhea and stomach pain; experts note the pill's approval and pricing leave affordability and access concerns for self‑pay patients.
Analysis
Center-leaning sources frame the introduction of the Wegovy pill as a significant innovation in weight-loss treatment, emphasizing its convenience and accessibility. They highlight the competitive landscape with Eli Lilly and the potential market impact. Language choices like "significant innovation" and "first and only" underscore the novelty, while structural choices focus on the pill's benefits and market availability, subtly promoting its adoption.